# SULANDA® (surufatinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/surufatinib

> SULANDA® (surufatinib), sponsored by HUTCHMED (China) Ltd (HCM), received a complete response letter from the FDA; the decision is dated Apr 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SULANDA® (surufatinib) |
| Codes |  |
| Sponsor | HUTCHMED (China) Ltd (HCM) https://sec-api.dev/companies/hcm/catalysts |
| Indications | [metastatic pancreatic ductal adenocarcinoma](https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma), pnets and non-pancreatic nets, pnets and epnets |
| Modality | small_molecule |
| FDA designations | fast track |

## Timeline

### Apr 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month. Indication: pNETs and non-pancreatic NETs.
- First seen 2025-03-19, last confirmed 2025-03-19.
- SEC Form 10-K (accession 0001410578-25-000377): "In April 2022, we received a Complete Response Letter from the FDA regarding the NDA for surufatinib for the treatment of pNETs and non-pancreatic NETs." https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm
- SEC Form 10-K (accession 0001410578-25-000377): "However, in April 2022, we received a Complete Response Letter from the FDA regarding the NDA for surufatinib for the treatment of pNETs and epNETs." https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm

### January 5, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 3. Indication: metastatic pancreatic ductal adenocarcinoma.
- First seen 2026-01-05, last confirmed 2026-07-30.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-088458): "The Phase III part of this study dosed first patient in December 2025, targeting enrollment of 400 patients with OS as the primary endpoint." https://www.sec.gov/Archives/edgar/data/1648257/000110465926088458/hcm-20260730xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-023831): "The Phase III part of this study dosed first patient in December 2025, targeting enrollment of 400 patients with OS as the primary endpoint." https://www.sec.gov/Archives/edgar/data/1648257/000110465926023831/tm2525075d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001648257-26-000002): "Hong Kong, Shanghai & Florham Park, NJ — Monday, January 5, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China." https://www.sec.gov/Archives/edgar/data/1648257/000164825726000002/hcm-20260105xex99d1.htm

## Same indication

- [Zabilugene almadenorepvec](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) (TOVX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/surufatinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SULANDA® (surufatinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/surufatinib

```bibtex
@misc{secapidev_pdufa_surufatinib_20261116,
  title        = {SULANDA® (surufatinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/surufatinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_surufatinib_20261116","title":"SULANDA® (surufatinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/surufatinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
